Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06506422
PHASE2/PHASE3

Empagliflozin Reversal of Arterial StiffnEss in Aging

Sponsor: University of Missouri-Columbia

View on ClinicalTrials.gov

Summary

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Official title: SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

Key Details

Gender

All

Age Range

60 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2024-08-18

Completion Date

2029-02-28

Last Updated

2026-02-06

Healthy Volunteers

Yes

Interventions

DRUG

Empagliflozin 10 MG

10mg Empagliflozin daily for 12 weeks

DRUG

Placebo

10mg Placebo daily for 12 weeks

Locations (1)

University of Missouri

Columbia, Missouri, United States